Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Clinical Investigations

Free Access

Prospective, Randomized Study on the Efficacy and Safety of Local UV-Free Blue Light Treatment of Eczema

Keemss K.a · Pfaff S.C.a · Born M.b · Liebmann J.b · Merk H.F.a · von Felbert V.a

Author affiliations

aDepartment of Dermatology and Allergology, University Hospital, RWTH Aachen University, and bPhilips GmbH, Innovative Technologies, Aachen, Germany

Corresponding Author

Dr. med. Verena von Felbert, PD

Department of Dermatology and Allergology

University Hospital, RWTH Aachen University

Pauwelsstrasse 30, DE-52074 Aachen (Germany)

E-Mail vvonfelbert@ukaachen.de

Related Articles for ""

Dermatology 2016;232:496-502

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Background: Blue light was shown to reduce the activation of T cells and modulate cytokine release in vitro. Therefore, we investigated the efficacy of blue light in the treatment of eczema. Methods: A sample of 21 patients with mild to moderate eczema were locally treated with blue LED light (light-emitting diode, emission maximum: 453 nm). They received light treatment 3 times per week for 4 weeks. A contralateral control lesion remained untreated. Results: A total of 20 patients completed the trial with a compliance rate of 100%. The blue light treatment was safe with no adverse events and no side effects. The primary end point change from baseline in the mean sum score of the local Eczema Severity Index (local ESI) was more pronounced for the treated area than for the control area (-1.9 ± 2.02 vs. -1.3 ± 2.24). The treatment difference was statistically significant (p = 0.0152, paired t test, two-sided). Conclusion: In this study UV-free blue light was safe and effective in the reduction of eczema lesions.

© 2016 S. Karger AG, Basel


References

  1. Becker D, Langer E, Seemann M, Seemann G, Fell I, Saloga J, Grabbe S, von Stebut E: Clinical efficacy of blue light full body irradiation as treatment option for severe atopic dermatitis. PLoS One 2011;6:e20566.
  2. Biagini Myers JM, Khurana Hershey GK: Eczema in early life: genetics, the skin barrier, and lessons learned from birth cohort studies. J Pediatr 2010;157:704-714.
  3. Brown S, Reynolds NJ: Atopic and non-atopic eczema. BMJ 2006;332:584-588.
  4. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J: Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol 2014;133:429-438.
  5. Darsow U, Wollenberg A, Simon D, Taïeb A, Werfel T, Oranje A, Gelmetti C, Svensson A, Deleuran M, Calza AM, Giusti F, Lübbe J, Seidenari S, Ring J; European Task Force on Atopic Dermatitis/EADV Eczema Task Force: Difficult to control atopic dermatitis. World Allergy Organ J 2013;6:6.
  6. Hoare C, Li Wan Po A, Williams H: Systematic review of treatments for atopic eczema. Health Technol Assess 2000;4:1-191.
  7. Fischer MR, Abel M, Lopez Kostka S, Rudolph B, Becker D, von Stebut E: Blue light irradiation suppresses dendritic cells activation in vitro. Exp Dermatol 2013;22:558-560.
  8. Hamilton FL, Car J, Lyons C, Car M, Layton A, Majeed A: Laser and other light therapies for the treatment of acne vulgaris: systematic review. Br J Dermatol 2009;160:1273-1285.
  9. Weinstabl A, Hoff-Lesch S, Merk HF, von Felbert V: Prospective randomized study on the efficacy of blue light in the treatment of psoriasis vulgaris. Dermatology 2011;223:251-259.
  10. Pfaff S, Liebmann J, Born M, Merk HF, von Felbert V: Prospective randomized long-term study on the efficacy and safety of UV-free blue light for treating mild psoriasis vulgaris. Dermatology 2015;231:24-34.
  11. Kleinpenning MM, Smits T, Frunt MH, van Erp PE, van de Kerkhof PC, Gerritsen RM: Clinical and histological effects of blue light on normal skin. Photodermatol Photoimmunol Photomed 2010;26:16-21.
  12. Krutmann J, Medve-Koenigs K, Ruzicka T, Ranft U, Wilkens JH: Ultraviolet-free phototherapy. Photodermatol Photoimmunol Photomed 2005;21:59-61.
  13. Liebmann J, Born M, Kolb-Bachofen V: Blue-light irradiation regulates proliferation and differentiation in human skin cells. J Invest Dermatol 2010;130:259-269.
  14. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M: The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11-18.

Article / Publication Details

First-Page Preview
Abstract of Clinical Investigations

Received: December 23, 2015
Accepted: May 20, 2016
Published online: August 19, 2016
Issue release date: September 2016

Number of Print Pages: 7
Number of Figures: 7
Number of Tables: 3

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.